

Day 1

Friday, May 3, 2024

7:00am	Registration Check-In / Breakfast
7:50	Welcome Address, House Keeping Items, Goals and Expectations Michael Wong, MD, PhD
8:00	Keynote Address: The Merkel Cell Carcinoma Landscape Paul Nghiem, MD, PhD
Session I	Polyoma Virus in Merkel Cell Carcinoma
8:30 – 10:00	Session Leader and Moderator: James DeCaprio, MD
8:30	Contributions of Merkel Cell Polyomavirus to Merkel Cell Carcinoma James DeCaprio, MD
8:45	MCC Insights from Whole Genome Sequencing Gabe Starrett, PhD
9:00	Mouse Model of Virus-Positive MCC Andrzej Dlugosz, MD
9:15	ALTO Downregulates NFkB Denise Galloway, PhD
9:30	MCPyV Infection in Skin Organoids Silvia Albertini, PhD
9:45	Q&A with Speakers Panel
Session II	Targeting Molecular Pathways in MCC
10:00 – 12:15	Session Leader and Moderator: Isaac Brownell, MD, PhD
10:00	Practical Perspective on the Discovery and Validation of MCC Therapeutic Targets Isaac Brownell, MD, PhD
10:15	Discovery and Disruption of Core Regulatory Transcription Factors in Merkel Cell Carcinoma Berkley Gryder, PhD
10:30	Targeting the DNA Replication (ATR) Checkpoint to Overcome Immunotherapy Resistance in Merkel Cell Carcinoma Rashmi Bhakuni, PhD
10:45	Targeting MDM2 in p53 Wildtype MCC: Rational and What Was Learned from the Navtemadlin Trial Michael Wong, MD, PhD
11:00	DNA Methylation: An Epigenetic Chink in the Armor of Merkel Cell Carcinoma Paul Harms, MD, PhD
11:15	Q&A with Speakers Panel
11:30	Morning Break and Networking
Noon	T Antigen–Specific CD8+ T Cells Associate with PD-1 Blockade Response in Virus-Positive Merkel Cell Carcinoma (<i>No CE Credit Awarded</i>) Sine Reker Hadrup, MD
12:15 pm	Q&A

12:20 – 1:10	Lunch (<i>to be provided</i>)
Session III 1:10 – 2:45	Immunobiology of MCC Session Leader and Moderator: Shailender Bhatia, MD
1:10	Introduction to Immunobiology of MCC Shailender Bhatia, MD
1:20	Emerging Biomarkers of Response to PD-1 Blockade Thomas Pulliam, MD, PhD Student
1:30	Optimal Duration of Anti-PD-(L)1 Immunotherapy Natalie Miller, MD, PhD
1:40	Updates on Intra-Tumoral Immunotherapy Andrew Brohl, MD
1:50	Immunotherapy in Organ Transplant Recipients Ann Silk, MD
2:00	Q&A with Speakers Panel
2:30	Afternoon Break and Networking
Session IV 2:45 -4:15	Pathology Insights into MCC Biology Session Leader and Moderator: Kenneth Tsai, MD, PhD
2:45	Perspective on the Pathophysiology of MCC Kenneth Tsai, MD, PhD
3:00	Resident CD8 and Vδ1 T Cells Functionally Converge to Drive Anti-Tumor Response in Merkel Cell Carcinoma Zachary Reinstein, BS [PhD]
3:15	The Current State of Diagnostic, Prognostic, and Predictive Markers for Merkel Cell Carcinoma Paul Harms, MD
3:30	Tumor Cell-Intrinsic PD-1 Promotes Merkel Cell Carcinoma Growth via mTOR-Mitochondrial ROS Signaling Tobias Schatton, PharmD, PhD
3:45	Combined Tumours as a Clue to Understand MCC Biology Thibault Kervarrec, PhD
4:00	Q&A with Speakers Panel
Session V 4:15 -5:30	Cellular Therapy: Coming of Age for Solid Tumors and MCC Session Leader and Moderator: Vernon Sondak, MD
4:15	Surgical Perspective on Cellular Therapy for MCC Vernon Sondak, MD
4:25	May the Fourth Be with You: Cellular Therapy, Attack of the Clones Cassian Yee, MD
4:45	BPXR1030: An Autologous Engineered T-Cell CAR Targeting GPC3 in MCC Ecaterina Dumbrava, MD
5:15	Q&A with Speakers Panel
5:15	Poster “Elevator Pitch” Session (No CE Credit Awarded)
5:30 – 7:00pm	Welcome Reception / Dinner – <i>Texas Themed</i>

Day 2 **Saturday, May 4, 2024**

7:00 am	Breakfast
8:00	Day 1 Highlights and Expectations for Day 2 Michael Wong, MD, PhD
8:10	Should Ipilimumab Be the New “Standard” for Refractory MCC? <i>(No CE Credit Awarded)</i> David Miller, MD, PhD
8:20	Morning Break and Networking
8:50	Updates on the Radiation Therapy of MCC Devarati Mitra, MD PhD
9:10	Q&A
9:20	How to Evaluate and Report Treatment Response After Adjuvant or Neo-Adjuvant Therapy Victor Prieto, MD, PhD
9:40	Q&A – Speakers Panel
9:45	Morning Break and Networking
Session VI 10:00 – 1:00	The Multidisciplinary Approach to MCC Diagnosis, Treatment and Follow Up PANEL DISCUSSION: Discussion Based on Real Life Cases Moderators: Merrick Ross, MD and Michael Wong, MD, PhD Panelists: Paul Harms, PhD, Devarati Mitra, MD, PhD, Natalie Miller, MD, PhD, Vernon Sondak, MD, Sunandana Chandra, MD
10:00	HOT TOPICS
10:20	Neoadjuvant Therapy – Who, What, When & How?
10:55	Surgical Approach – How Much is Enough? Biopsy Lymph Nodes?
11:15	Adjuvant therapy – the New Standard for Everyone?
11:35	Radiation Therapy – Cure, Palliation, Adjunctive
11:55	Advanced Disease – PD-1 Monotherapy or with Anti-CTLA4 or Others
12:15 pm	Summary / Conclusion
12:15	Morning Break and Networking
12:30	PANEL DISCUSSION Moderator: Paul Nghiem, MD PhD Panelists: Drs. Shailender Bhatia, MD, Andrew Brohl, MD, Isaac Brownell, MD, PhD, James DeCaprio MD, Kelly Harms, MD, Merrick Ross MD, Ken Tsai MD PhD
	Unmet Needs and Knowledge Gaps – What Are We Doing on Monday? Clinical Trials: The “Art of the Possible” in a Rare Disease
1:00	Concluding Remarks – Meeting Adjournment Michael Wong, MD, PhD
1:10	Meeting Ends – <i>Grab & Go Lunches</i>

Third International Merkel Cell Carcinoma Conference
5/3/2024 - 5/4/2024
7:50:00 AM - 1:10:00 PM

Target Audience:

Professions: Physician (MD or DO), Physician Associate, Other

Description:

The Merkel Cell Carcinoma (MCC) conference is a dedicated platform designed to delve into the latest emerging data, shedding light on the fundamental biology driving this disease. It serves as a catalyst for refining clinical guidelines and cultivating innovative approaches to tackle MCC effectively. The conference showcases recent updates from clinical guidelines and highlights cutting-edge insights into MCC biology through its plenary sessions. Its overarching educational mission is to disseminate this evolving data widely, fostering a stimulating and collaborative environment to propel MCC research forward.

Learning Objectives:

- 1 Demonstrate enhanced proficiency in Merkel Cell Carcinoma (MCC) management by integrating updated knowledge and strategies.
- 2 Apply evidence-based practices for optimal patient care in clinical settings.
- 3 Employ the latest advancements in Merkel Cell Carcinoma (MCC) management, demonstrating the ability to integrate emerging data and guidelines into clinical practice to improve patient outcomes.
- 4 Discuss how to effectively apply evolving guidelines and advancements in MCC treatment within clinical practice.

Accreditation:



In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 11.25 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Financial Relationships:

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty & Planner Disclosure:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Eric Gagneaux	Activity Administrator	Nothing to disclose - 01/15/2024
Phyu Aung, MD, PhD	Faculty, Other Planning Committee Member	Nothing to disclose - 11/16/2023

Contact us: ContinuingEducation@mdanderson.org

PEP Website: www.mdanderson.cloud-cme.com

Ecaterina E Dumbrava, MD	Faculty	Advisor-BOLT Therapeutics Advisor-Mersana Advisor-Orum Therapeutics Advisor-Summit Therapeutics Grant or research support-Bayer HealthCare Pharmaceuticals, Inc. Grant or research support-Immunocore LTD Grant or research support-Amgen Inc. Grant or research support-Aileron Therapeutics Grant or research support-Compugen Ltd Grant or research support-TRACON Pharmaceuticals Inc Grant or research support-Unum Therapeutics Grant or research support-Gilead Sciences, Inc. Grant or research support-BOLT Therapeutics Grant or research support-Aprea Therapeutics Grant or research support-Bellicum Pharmaceuticals Grant or research support-PMV Pharma Grant or research support-Triumvira Grant or research support-Seagen Inc Grant or research support-Mereo BioPharma 5 Inc Grant or research support-Sanofi Grant or research support-Rain Oncology Grant or research support-Astex Therapeutics Grant or research support-Sotio Grant or research support-Mersana Therapeutics Grant or research support-Genentech Grant or research support-Boehringer Ingelheim Other: Consult (non-paid)-Catamaran Bio Speakers Bureau-PMV Pharma Other: Travel, Accommodations, Expenses-ASCO Other: Travel, Accommodations, Expenses-LFSA Association Other: Travel, Accommodations, Expenses-Rain Oncology Other: Travel, Accommodations, Expenses-Banner MD Anderson Cancer Center - 09/25/2023
Victor G Prieto, MD, PhD, USCAP, ASDP, ISDP, CAP, ASCP	Faculty	Consulting Fee-Myriad (Relationship has ended) Consulting Fee-Orlucent Consulting Fee-Castle Biosciences, Inc. - 04/23/2024
Merrick I Ross, MD, FACS	Faculty, Other Planning Committee Member	Consulting Fee-Merck Sharp & Dohme Corp. (any division) Honoraria-Merck Sharp & Dohme Corp. (any division) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division) - 09/11/2023
Michael K. Wong, MD, PhD, FRCPC	Course Director, Faculty	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc. Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron Pharmaceuticals, Inc. Membership on Advisory Committees or Review Panels, Board Membership, etc.-EMD Serono Inc. Membership on Advisory Committees or Review Panels, Board Membership, etc.-Castle Biosciences, Inc. - 01/14/2024
Devarati Mitra, MD, PhD	Faculty, Other Planning Committee Member	Nothing to disclose - 11/03/2023
Cassian Yee, MD	Faculty	Nothing to disclose - 04/23/2024
Asya Hayes, BA, Public Administration	Other Planning Committee Member	Nothing to disclose - 03/03/2024

Contact us: ContinuingEducation@mdanderson.org

PEP Website: www.mdanderson.cloud-cme.com

Shailender Bhatia, MBBS, MD	Faculty	Grant or research support-4SC Honoraria-Bristol-Myers Squibb Company (Relationship has ended) Honoraria-Incyte Corporation (Relationship has ended) Other: Travel support-Regeneron Pharmaceuticals, Inc. (Relationship has ended) Grant or research support-Agenus Grant or research support-Amphivena Grant or research support-Bristol-Myers Squibb Company Grant or research support-Regeneron Pharmaceuticals, Inc. Grant or research support-EMD Serono Inc. Grant or research support-Excure (Relationship has ended) Grant or research support-Immune Design (Relationship has ended) Grant or research support-Incyte Corporation Grant or research support-Kuni Foundation Grant or research support-Merck Sharp & Dohme Corp. (any division) Grant or research support-Nektar Therapeutics (Relationship has ended) Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended) Grant or research support-TriSalus Life Sciences Grant or research support-Xencor - 04/02/2024
Isaac Brownell, MD, PhD	Faculty	Nothing to disclose - 03/03/2024
Paul Nghiem, MD, PhD	Faculty	Grant or research support-Incyte Corporation - 04/26/2024
Kenneth Tsai, MD, PhD	Faculty	Consulting Fee-NFlection Therapeutics Independent Contractor (included contracted research)-Worldcare Clinical Independent Contractor (included contracted research)-Verrica Pharmaceuticals - 03/04/2024
Gabriel Starrett, PhD	Faculty	Nothing to disclose - 04/02/2024
Vernon K Sondak, MD	Faculty	Consulting Fee-Bristol-Myers Squibb Company Consulting Fee-Genesis Drug Discovery & Development Consulting Fee-Helix Biopharma Paid consultant-Iovance Biotherapeutics Paid consultant-Merck Sharp & Dohme Corp. (any division) Paid consultant-Mural Oncology Paid consultant-Novartis Pharmaceuticals Corporation Paid consultant-Sun Pharmaceuticals Grant or research support-Neogene Therapeutics Grant or research support-Skyline and Turnstone - 04/29/2024
Natalie J Miller, MD, PhD	Faculty	Nothing to disclose - 04/23/2024
Kelly Harms, MD, PhD	Faculty	Nothing to disclose - 04/23/2024
James DeCaprio, MD	Faculty	Grant or research support-Kymera Therapeutics Consulting Fee-Kymera Therapeutics Consulting Fee-Mariana Oncology Grant or research support-Rain Therapeutics (Relationship has ended) - 04/29/2024
Zachary Zale Reinstein, BS	Faculty	Nothing to disclose - 04/11/2024
Silvia Albertini, PhD	Faculty	Nothing to disclose - 04/05/2024
Sunandana Chandra, MD	Faculty	Advisor-Bristol-Myers Squibb Company Advisor-Regeneron Pharmaceuticals, Inc. (Relationship has ended) Advisor-Pfizer Inc. (Relationship has ended) Advisor-Novartis Pharmaceuticals Corporation (Relationship has ended) Advisor-

Contact us: ContinuingEducation@mdanderson.org

PEP Website: www.mdanderson.cloud-cme.com

		Excicure (Relationship has ended) Advisor-EMD Sero Inc. (Relationship has ended) - 04/25/2024
Thibault Kervarrec, MD, PhD	Faculty	Nothing to disclose - 04/05/2024
Thomas H Pulliam, PhD	Faculty	Nothing to disclose - 04/23/2024
Rashmi Bhakuni, PhD	Faculty	Nothing to disclose - 04/12/2024
Tobias Schatton, PharmD, PhD	Faculty	Nothing to disclose - 04/21/2024
Paul Harms, MD, PhD	Faculty	Other: Effort support for clinical trial correlatives-Certa Therapeutics (Relationship has ended) - 04/23/2024
Andrzej Dlugosz, MD	Faculty	Nothing to disclose - 04/23/2024
Berkley Gryder, PhD	Faculty	Nothing to disclose - 04/23/2024
Andrew S Brohl, MD	Faculty	Nothing to disclose - 04/24/2024
Denise Galloway, PhD	Faculty	Nothing to disclose - 04/24/2024
Ann W. Silk, MD	Faculty	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Natera (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron Pharmaceuticals, Inc. (Relationship has ended) Stocks or stock options, excluding diversified mutual funds-Illumina - 04/24/2024

REQUIREMENTS FOR SUCCESSFUL ACTIVITY COMPLETION:

To claim CE credits or contact hours for this activity, the participant must:

- **Have a profile in Professional Education Portal (PEP):**
 1. Create an account and complete profile in (PEP).
 2. Pair your email address to PEP (must use email address used to create PEP account). This is a **one-time** step in order to log your attendance using the text messaging feature in the future. Pairing your phone to the system is done by sending a **text** of your **email address** to **1-844-912-1333**.
- **Register** for and attend all sessions of this activity.
- **Record Attendance:** During the activity, the learner will TEXT the code:32663 to **1-844-912-1333**. Learners have up to 24 hours after the activity has ended to text this code in order to record attendance.
- **Evaluation:** Complete the participant evaluation in PEP within 30-days.
- **Claim Credit:** Claim your CE credits. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:

No commercial support has been received for this activity.

Contact us: ContinuingEducation@mdanderson.org

PEP Website: www.mdanderson.cloud-cme.com

EXHIBITORS

The conference organizing committee wishes to express appreciation to the following companies:

GOLD LEVEL

Regeneron Pharmaceuticals

BRONZE LEVEL

Merck